Journal article
Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension
V Shenoy, KC Kwon, A Rathinasabapathy, S Lin, G Jin, C Song, P Shil, A Nair, Y Qi, Q Li, J Francis, MJ Katovich, H Daniell, MK Raizada
Hypertension | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014
Abstract
Emerging evidences indicate that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin-converting enzyme 2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to the pathogenesis of pulmonary hypertension (PH). However, long-term repetitive delivery of ACE2 or Ang-(1-7) would require enhanced protein stability and ease of administration to improve patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect against gastric enzymatic degradation and facilitates long-term storage at room temperature. Besides, fusion to a transmucosal carrier helps effecti..
View full abstractGrants
Awarded by National Institute of General Medical Sciences
Funding Acknowledgements
This study was supported by National Institutes of Health grants (HL099980 and HL102033 to M. K. Raizada and M.J. Katovich, Co-PIs, HL106687, and HL109442 to H. Daniell, and EY021752 to Q. Li), an American Heart Association Scientist development grant (SDG12080302 to V. Shenoy)